Hypoglycaemia News and Research

RSS

European Commission approves ONGLYZA as combination therapy with insulin for type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved ONGLYZA (saxagliptin) for use as a combination therapy with insulin (with or without metformin) to improve blood sugar (glycaemic) control in adult patients with type 2 diabetes.

28 Nov 2011

Scientists discover rare genetic alteration responsible for hypoglycaemia

Cambridge scientists have identified the cause of a rare, life-threatening form of hypoglycaemia. Their findings, which have the potential to lead to pharmaceutical treatments for the disorder, were published today, 07 October, in the journal Science.

7 Oct 2011

Lack of communication between diabetes patients and physicians around hypoglycaemia: Survey

New multinational survey data released to coincide with the European Association for the Study of Diabetes (EASD) 47th Annual Meeting has revealed a lack of communication between type 2 diabetes patients and physicians around hypoglycaemia.

15 Sep 2011

Novo Nordisk's insulin degludec reduces blood sugar in patients with type 2 diabetes

Ultra-long-acting insulin degludec, an investigational basal insulin being developed by Novo Nordisk, showed significant blood sugar reductions in patients with type 2 diabetes.

From Novo Nordisk 15 Sep 2011

IQWiG publishes results of literature search on DMP for diabetes mellitus type 1

On 22 August 2011, the German Institute for Quality and Efficiency in Health Care (IQWiG) published the results of a literature search for evidence-based clinical practice guidelines on the treatment of people with diabetes mellitus type 1.

3 Sep 2011

Living Cell Technologies xenoimplants first patients in Argentina trial

Living Cell Technologies Limited has implanted the first two patients taking part in a Phase II DIABECELL® clinical trial in Buenos Aires, Argentina.

22 Aug 2011

Intensive glycaemic control may negatively affect a person's quality of life

Research published in The Cochrane Library found that the risk of death and cardiovascular disease, such as stroke, was unchanged whether glucose control was intense or conventional.

1 Aug 2011

Channel Swim Relay event aims to raise money for JDRF

Six swimmers congregate along the Dover coastline today, to participate in a 17-hour relay swim across the English Channel to France. The relay event, sponsored by Animas,aims to raise money for the Juvenile Diabetes Research Foundation (JDRF) and celebrate people with diabetes performing at their best.

21 Jul 2011

Boehringer Ingelheim, Lilly announce new data from linagliptin Phase III study on type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today announced Phase III study results for linagliptin, demonstrating improved glycaemic control in adults with type 2 diabetes (T2D) whose blood glucose is not adequately maintained.

27 Jun 2011

Boehringer Ingelheim, Eli Lilly receive FDA approval for linagliptin to treat type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today announced that the U.S. Food and Drug Administration has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

3 May 2011

Diabetes cell implant company approved for Argentina clinical trial

Living Cell Technologies Limited, a company pioneering the development of a cell implant to treat diabetes, has obtained approval to commence a Phase II DIABECELL clinical trial in Buenos Aires, Argentina, DIABECELL's third jurisdiction to date which has approved human trials. Up to eight adult patients with Type 1 diabetes, including those with unstable diabetes and severe hypoglycaemia, will each receive two implants of DIABECELL, three months apart with a dose seeking component. The trial is expected to begin in the second half of this year.

3 May 2011

Novo Nordisk first quarter net profit increases 23% to DKK 4,073 million

Novo Nordisk has completed a pre-specified meta-analysis based on the Degludec phase 3a trial programme. The meta-analysis confirmed that Degludec is associated with a lower risk of hypoglycaemia compared to insulin glargine, both on the total number of confirmed hypoglycaemic events, and on the number of confirmed nocturnal hypoglycaemic events. Both findings are statistically significant.

From Novo Nordisk 28 Apr 2011

Leading foundations support Australian diabetes treatment

Two international charitable foundations, New Zealand-based Cure Kids and U.S.-based Children with Diabetes Foundation, have each pledged to provide US$140,000 to fund the final two patients in a Phase II clinical trial in New Zealand that has the potential to transform the treatment of Type 1 diabetes.

15 Feb 2011

New positive data on Generex Oral-lyn published in Diabetes, Obesity and Metabolism

Generex Biotechnology Corporation announced today that the peer-reviewed scientific journal Diabetes, Obesity and Metabolism has published new positive data in respect of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product.

13 Dec 2010

Linagliptin clinical trial data shows positive result for type 2 diabetes treatment

New data from the linagliptin late stage clinical trial programme were presented this week at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD).

23 Sep 2010

Linagliptin mono- and combination therapy improves blood glucose control

Linagliptin phase III data were presented for the first time this week at the 70th Scientific Sessions of the American Diabetes Association (ADA), showing that this investigational compound, a dipeptidyl peptidase (DPP)-4 inhibitor, achieved significant, sustained and clinically meaningful reductions in blood glucose as measured by haemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and postprandial glucose (PPG) concentrations.(1-6) Linagliptin is being investigated by Boehringer Ingelheim as a once-daily oral treatment in type 2 diabetes.

28 Jun 2010

Study recommends women to avoid drug abuse during prenatal and breastfeeding periods

Give up smoking, do not drink more than three cups of coffee per day, do not take any kind of drug, or if you do, take it as long as possible before feeding your baby. These are some of the recommendations contained in a study produced by Spanish researchers on methods for detecting medicines and drugs in breast milk. The study shows that the risk from substances such as alcohol is still not well understood.

24 Jun 2010

Roche implements risk mitigation plan in taspoglutide Phase III programme

Ipsen, a global biopharmaceutical group, today announced that its partner Roche today announced the implementation of a risk mitigation plan in the taspoglutide Phase III programme. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen's research is developed by Roche. This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation.

18 Jun 2010

Additional benefits of LAIAs over long-acting human insulin not been proven

It has so far not been proven that the long-acting insulin analogues (LAIAs) insulin detemir (trade name: Levemir) and insulin glargine (trade name: Lantus), which are approved for the treatment of type 1 diabetes, offer patients an additional benefit versus long-acting human insulin. This applies to adults as well as to children and adolescents. This is the result of the final report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 19 April 2010.

13 May 2010

LCT receives grant of $500,000 for Phase II clinical trial of DIABECELL in New Zealand

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, has received a grant of US$500,000 for its on-going Phase II clinical trial of DIABECELL in New Zealand from the Juvenile Diabetes Research Foundation International, a world leader in setting the agenda for diabetes research and the largest charitable funder and advocate for research in type 1 diabetes.

27 Apr 2010